CV Sciences (CVSI) Other Non Operating Income (2014 - 2026)
CV Sciences (CVSI) reported Other Non Operating Income of $20000.0 for Q1 2026, down 47.37% on a YoY basis from $38000.0 in Q1 2025, and down 94.94% sequentially from $395000.0 in Q4 2025.
CV Sciences (CVSI) Other Non Operating Income (2014 - 2026) Analysis & Trends
CV Sciences (CVSI) has 11 years of Other Non Operating Income data on file, last reported at $20000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 47.37% year-over-year to $20000.0; the trailing twelve-month figure through Mar 2026 stood at $415000.0 (up 638.96% YoY), and the FY2025 full-year result was $7000.0, changed N/A from the prior year.
- Other Non Operating Income declined to $20000.0 in Q1 2026, from $395000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $1.3 million in Q4 2022 to a low of -$336000.0 in Q2 2022.
- A 5-year average of $123250.0 and a median of -$6000.0 in 2023 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income plunged 1050.0% in 2024 and surged 2000.0% in 2025, its largest moves.
- Tracing CVSI's Other Non Operating Income over 5 years: stood at $1.3 million in 2022, then plunged by 47.55% to $695000.0 in 2023, then slumped by 116.55% to -$115000.0 in 2024, then surged by 443.48% to $395000.0 in 2025, then sank by 94.94% to $20000.0 in 2026.
- Business Quant data shows CVSI's Other Non Operating Income at $20000.0 in Q1 2026, $395000.0 in Q4 2025, and $38000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.24 Bn | 87.37 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.28 Bn | 21.13 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.54 Bn | 20.54 Bn | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.55 Bn | 12.12 Bn | 785.00 Mn |
| 10 | CV Sciences | 4.11 Mn | 3.80 Mn | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20,000.00 |
| Dec 31, 2025 | 395,000.00 |
| Mar 31, 2025 | 38,000.00 |
| Sep 30, 2024 | -115,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | 695,000.00 |
| Sep 30, 2023 | -10,000.00 |
| Jun 30, 2023 | -209,000.00 |
| Mar 31, 2023 | -56,000.00 |
| Dec 31, 2022 | 1.33 Mn |
| Sep 30, 2022 | -266,000.00 |
| Jun 30, 2022 | -336,000.00 |
| Sep 30, 2021 | 2.95 Mn |
| Dec 31, 2018 | -2,614.00 |
| Dec 31, 2017 | -767,875.00 |
| Sep 30, 2017 | 10,987.00 |
| Jun 30, 2017 | -132,514.00 |
| Mar 31, 2017 | 210,600.00 |
| Dec 31, 2016 | -1.07 Mn |
| Sep 30, 2016 | -321,006.00 |